[go: up one dir, main page]

AR020741A1 - COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES - Google Patents

COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES

Info

Publication number
AR020741A1
AR020741A1 ARP990105083A ARP990105083A AR020741A1 AR 020741 A1 AR020741 A1 AR 020741A1 AR P990105083 A ARP990105083 A AR P990105083A AR P990105083 A ARP990105083 A AR P990105083A AR 020741 A1 AR020741 A1 AR 020741A1
Authority
AR
Argentina
Prior art keywords
composition
allergic diseases
treat allergic
effective amount
treat
Prior art date
Application number
ARP990105083A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR020741A1 publication Critical patent/AR020741A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica util para el tratamiento de la rinitis alérgica, el asma y trastornos relacionados. En una realizacion, la composicion comprende,en combinacion, una cantidad terapéuticamente efectiva de al menos un antagonista deneuroquinin a, una cantidad efectiva de al menos un inhibidor de5-lipoxigenasa.Useful pharmaceutical composition for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one deneuroquinin antagonist a, an effective amount of at least one 5-lipoxygenase inhibitor.

ARP990105083A 1998-10-09 1999-10-07 COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES AR020741A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16960998A 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
AR020741A1 true AR020741A1 (en) 2002-05-29

Family

ID=22616408

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105083A AR020741A1 (en) 1998-10-09 1999-10-07 COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES

Country Status (9)

Country Link
EP (1) EP1119372A1 (en)
JP (1) JP2002527406A (en)
CN (1) CN1329505A (en)
AR (1) AR020741A1 (en)
AU (1) AU6391199A (en)
CA (1) CA2346228A1 (en)
CO (1) CO5140080A1 (en)
PE (1) PE20001095A1 (en)
WO (1) WO2000021564A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560559B2 (en) * 2003-04-15 2009-07-14 Merck & Co., Inc. Polymorphic form of montelukast sodium
EP1997491B1 (en) * 2004-07-14 2010-09-22 Inflammation Research Center Company Ltd. Method for inhibiting tumor metastasis
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
GB9521781D0 (en) * 1995-10-24 1996-01-03 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
JP2002527406A (en) 2002-08-27
WO2000021564A1 (en) 2000-04-20
CO5140080A1 (en) 2002-03-22
CA2346228A1 (en) 2000-04-20
CN1329505A (en) 2002-01-02
AU6391199A (en) 2000-05-01
PE20001095A1 (en) 2000-10-31
EP1119372A1 (en) 2001-08-01

Similar Documents

Publication Publication Date Title
DE69529912D1 (en) USE OF THE SECRETORIC LEUCOCYTAR PROTEASE INHIBITOR (SLPI) AS A TRYPTASE INHIBITOR
MY134110A (en) Combinations of reboxetine and neuroleptic agents
PT971713E (en) USE OF COLINESTERASE INHIBITORS FOR TREATMENT OF ATENTION DISORDERS
PE20020521A1 (en) SUBSTITUTE HETEROCYCLIC COMPOUNDS TO TREAT MULTIPLE DRUG RESISTANCE
BR0112756A (en) Compound, pharmaceutical composition, methods for treating prostaglandin-mediated diseases, nasal congestion, allergic asthma, and allergic rhinitis, and use of a compound
BR0311375A (en) Pharmaceutical composition, use thereof, and method for treating dementia or mild cognitive impairment in a mammal
SE9803710D0 (en) Use of certain drugs for treating nerve root injury
DE60134547D1 (en) PARTICULARIZED CORTICAL BONE CONSTRUCTIONS
BR0316203A (en) Use of an antiallergic agent and a steroid to treat allergic rhinitis
NO20060328L (en) Combination of mGluR2 antagonist and ACHE inhibitor for the treatment of acute and / or chronic neurological disorders
BR0211274A (en) Combination of an aldosterone receptor antagonist and an hmg co-reductase inhibitor
EP1769797A3 (en) Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
AR020740A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES
BR0214643A (en) Application of an h1 antagonist, and a safe steroid to treat rhinitis
AR020741A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
BG106748A (en) Method and compositions for treating pulmonary diseases
PT1071463E (en) METHODS AND COMPOSITIONS USING METABOLITES OF TERFENADINE IN COMBINATION WITH LEUCOTRIENE INHIBITORS
AR019327A1 (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
ECSP993167A (en) COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES
ECSP993168A (en) COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES
AU2003259198A8 (en) Method and composition for treating and preventing influenza infection and symptoms thereof
WO2000054770A8 (en) Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
BR0013665A (en) Use of a histacaline protein, pharmaceutical composition, and method of treating or preventing conjunctivitis
NO20053247D0 (en) Use of levocetirizine in the treatment of persistent allergic rhinitis.

Legal Events

Date Code Title Description
FB Suspension of granting procedure